Definium Therapeutics succeeds in DT120 ODT Phase 3 clinical trial and plans to submit new drug application in first half of 2027
DFTX Definium Therapeutics Inc
$34.64 -2.12%
View chart & analysis → - 1Definium Therapeutics has transitioned to the regulatory submission and commercialization preparation stage following positive Phase 3 clinical trial results for DT120 ODT.
- 2The FDA has granted Breakthrough Therapy Designation to DT-120 ODT for the treatment of major depressive disorder and generalized anxiety disorder.
- 3As of September 30, 2026, Definium Therapeutics has a cash balance of approximately $1.05 billion.
So what's the key point?
Definium Therapeutics has successfully completed the final trials for its treatment for depression and anxiety disorders. The company is preparing to apply for new drug approval using its $1.05 billion cash reserve.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.